You searched for "safety"
HOYA Vision Care’s Defocus Incorporated Multiple Segments Spectacle Lenses demonstrated significant trend of myopia control in children
Interim analysis from the Observational French Study in children presented at EPOS 2024 meeting in Paris. Data from an interim analysis of the Observational French Study, OPHTAMYOP, has demonstrated a significant trend of myopia control in children with spherical equivalent...The College of Optometrists publishes updated Clinical Governance Guidance to support quality improvement and excellence in optometry
The College of Optometrists has launched its updated Clinical Governance Guidance to provide members with a robust framework that aligns with the healthcare landscape and primary care optometry workplace practices of today - and into the future. The guidance will...
Intravitreal dexamethasone implant for recurrent CMO secondary to IGS
1 February 2017
| Sofia Rokerya
|
EYE - Vitreo-Retinal
In this prospective study the authors present the data obtained on the efficacy and safety of the dexamethasone implant (0.7 mg) in the treatment of recurrent cystoid macular oedema (PCME) due to Irvine–Gass syndrome in patients with uncomplicated pseudophakia (off-label...
Intravitreal bevacizumab vs. ranibizumab in the treatment of macular oedema due to BRVO
This is a randomised, prospective, non-inferiority trial of 75 patients with macular oedema due to a branch retinal vein occlusion (BRVO) who received intravitreal injections of ranibizumab or bevacizumab after 1:1 block randomisation. This study is to measure the difference...
IVTA for diabetic macular edema and macular edema secondary to retinal vein occlusion: a meta-analysis
1 August 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This meta-analysis aimed to compare the safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular oedema (DME) and macular oedema (ME) secondary to retinal vein occlusion (RVO). A systematic literature search for randomised controlled trials...
Sight Sciences Glaucoma Fellows Academy, Birmingham
20 October 2023
|
Research & Development, Recruitment & Personnel, Awards, Conferences & Anniversaries
Saturday 7 October saw Sight Sciences hold their inaugural UK Glaucoma Fellows Academy training day.
Oertli Instrumente AG achieves milestone with FDA 510(k) clearance for Faros surgical system
24 July 2024
|
Research & Development
Oertli Instrumente AG, a leader in innovative surgical solutions for ophthalmology, is proud to announce the U.S. Food and Drug Administration (FDA) 510(k) clearance for the worldwide established Faros anterior cataract surgery system. This milestone underscores Oertli's global reach and...
Addressing medical risk factors for diabetes and understanding the new systemic treatments
1 February 2014
| Samantha S Mann
As global diabetes figures continue to rise, the importance of reducing the burden of macrovascular and microvascular complications of diabetes has never been so great. By 2025 it is estimated that five million people in the UK will have diabetes...
The results of the last survey Jun25
The first question refers to whether we check blood glucose levels prior to cataract surgery. Almost three quarters of you do which was interesting. We know that poor glycaemic control (manifesting as a raised HbA1c) has implications for wound healing...More action on sepsis needed as NHS Ombudsman still seeing same failings a decade on
The UK’s Health Ombudsman has warned that sepsis is still taking too many lives due to the same hospital failings we were seeing over ten years ago.WATCH EPISODE 9: Beyond 2020 with the Andean Medical Mission
21 February 2024
|
AMM, CHARITY, INTERNATIONAL, WORKING ABROAD, DAVE GOLDSMITH, CATARACT SURGERY, RURAL AREAS
Welcome to the 9th episode of Beyond 2020, the series that looks at strategies to eliminate avoidable blindness in countries with developing eyecare services and shares ideas and solutions to common difficulties in working abroad.
UK Glaucoma Fellows Meeting 2023
7 October 2023
09:00 - 09:30 Welcome 09:30 - 09:45 Introduction: Mr. Imran Masood (Participants split into 4 small groups, then cycle around the sessions) 10:00 – 13:00 Session 1 Introducing new technologies to NHS trusts Imran Masood Session 2 Optimising Patient Safety...
